Status:
RECRUITING
Communicating Uncertainties Associated With the Benefits and Risks of New Cancer Drugs
Lead Sponsor:
London School of Economics and Political Science
Collaborating Sponsors:
Harvard Medical School / Harvard Pilgrim Health Care Institute
Conditions:
Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This nationally representative randomized survey of US adults will evaluate the effect of using brief statements to communicate different sources of uncertainty about the benefits and harms of new can...
Detailed Description
Many newer cancer drugs are approved before uncertainties with their underlying clinical trial evidence have been adequately studied, in turn making it difficult to accurately determine the drug's ben...
Eligibility Criteria
Inclusion
- Adults 18 years of age and older
- Adults fluent in English
- Adults residing in the United States
Exclusion
- Participants who do not meet each of the 3 inclusion criteria
Key Trial Info
Start Date :
May 9 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2025
Estimated Enrollment :
3000 Patients enrolled
Trial Details
Trial ID
NCT06997185
Start Date
May 9 2025
End Date
June 1 2025
Last Update
May 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Harvard Medical School and Harvard Pilgrim Health Care Institute
Boston, Massachusetts, United States, 02139